Navigation Links
Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
Date:4/2/2012

for our shareholders.  Nowhere is this potential more obvious than in type 2 diabetes, where we have what we believe to be a once-in-a-lifetime opportunity to help the hundreds of millions of patients worldwide challenged by this devastating disease.  I am also looking forward to building on our innovative drug delivery platforms and our state-of-the-art manufacturing facility in California while we open our new headquarters in the Boston area, a region with deep resources and unparalleled innovation networks to support a growing life science company."

About ITCA 650
ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy comprises Intarcia's DUROS delivery device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time. The combined technologies can deliver up to a full year of injection-free therapy from a single ITCA 650 placement.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as a twice-daily and once-weekly self-injection therapy for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. Intarcia's robust intellectual pro
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
6. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... ... 2020 from $107.56 million in 2015, growing at a CAGR of 17.89% between ... aptamers, RNA-based aptamers, and XNA-based aptamers. Based on applications, the report is segmented ...
(Date:7/7/2015)... ... July 07, 2015 , ... Since its inception in ... What began as a conference for European Statistical Programmers, has evolved in the ... biometrical area. Statistical Programmers, Data Managers and Biostatisticians all over the world, share, ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... CSM, a ... team as Vice President of Finance. Morse has an extensive background in financial management ... to the CSM team. In his new role, Morse will oversee all financial areas ...
(Date:7/7/2015)... ... July 07, 2015 , ... Currently ... system was developed to solve many of the complex logistical and data ... that involve multiple clinical sites and/or remote data coordination centers. , CentrePoint ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5PhUSE Delighted to Welcome Member Number 5.000 2CSM Appoints Michael Morse as Vice President of Finance 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3
... Madison, Wis. - The parent company of a ... the voluntary nature of the product following the signing ... from requiring them to be implanted. , ,Scott Silverman, ... VeriChip Corp., said the company's practices are consistent with ...
... Claire, Wis. - Tundra Semiconductor Corp. , ... communications and computing markets, has announced the acquisition of ... design company based in Eau Claire, for $14 million. ... Claire as a division of Tundra Semiconductor Corp. The ...
... M. Price about his book "The Eye For Innovation: ... includes his comments about business, strategy, innovation and "the ... he writes, "business strategy is about people." , ... led Control Data Corp. (CDC) from a hardware-only firm ...
Cached Biology Technology:Company defends RFID implant product 2Canadian firm acquires Silicon Logic 2New book from former CDC CEO walks readers through innovation 2New book from former CDC CEO walks readers through innovation 3New book from former CDC CEO walks readers through innovation 4
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... tissue during surgical operations has the potential to produce ... conventional sutures and stapling in intestinal surgery, scientists are ... solder, or sealing material, appears in the journal ... explain that laser tissue welding (LTW) is a "stitch-free" ...
... provider of scientific, technical and medical information products and ... by the European Menopause and Andropause Society (EMAS) in ... peri and postmenopausal women with summary recommendations. The ... of the endometrium and premalignant endometrial hyperplasia. Assessment of ...
, This press release is available in spanish . Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing, ,...
Cached Biology News:
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
supplied with 10x reaction buffer...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
Biology Products: